×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Osteoarthritis Market Share

ID: MRFR/Pharma/1078-HCR
90 Pages
Rahul Gotadki
October 2025

Osteoarthritis Market Research Report Information By Type (Hip Osteoarthritis, and Spinal Osteoarthritis), By Diagnosis (Imagining, and Joint Fluid Analysis), By Treatment (Medication, Surgery, Therapy), By End-User (Hospitals, and Medical Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Osteoarthritis Market Infographic
×
Osteoarthritis Market Infographic Full View
Purchase Options

Market Share

Osteoarthritis Market Share Analysis

Payment processors and healthcare companies can make more money by doing things other than what they normally do. When looking for new ways to make money, they could, for instance, focus on healthcare technology and services. To grow, many healthcare groups depended on slow or spontaneous changes. For example, putting more attention on healthcare areas that aren't essential could speed up progress in the future; early data shows that spending money on these areas can pay off. The ability to diversify can assist businesses in starting up new ones. Some examples are payers becoming more involved in care management to better deal with population risk, or providers adding digital services (such as telemedicine or technology-enabled care management) to connect with patients better and adapt to changes in how care is provided. Globalization helps companies get more customers, hire new workers, make more money, and bring in more cash. Getting a business started in a new market can cost a lot, so businesses think carefully about where they are now before making a plan to expand internationally. As a result, companies carefully study the rules of each new market before choosing if it makes sense to do business there. In order to help people with osteoarthritis deal with their symptoms and slow down the disease's progression, scientists are working harder to make medicines. To help patients in the long run, treatments that deal with the causes of inflammation and repair of cartilage are used. Because it can make it easier for more people to get high-quality healthcare, improve worker health and output, and lead to better results, digital health is essential. Patient engagement tools, telemedicine platforms, and mobile apps can all help patients get real-time information and manage their arthritis symptoms. The latest arthritis apps are starting to include functions that are good for the earth. This means making things in eco-friendly ways, properly throwing away trash, and trying to make treatments for osteoarthritis less harmful to the environment. The toughness of a delivery network is measured by how quickly it can fix issues and perform normally again. One way to do this is to make sure that supply chain problems don't happen too often and aren't too bad when they do. A lot of the supply chain can be affected by operational risk and uncertainty, which can finally weaken the company. Disasters on a global scale, like the COVID-19 spread, can have a big effect on job markets, suppliers, and the supply chain operations. There may be problems in the supply chain if there is quick competition, changes in the market, or even changes in the way people buy things. The most adaptable and strong supply networks can't just fix themselves when they get broken. They can see ahead and act quickly on any chances or dangers that might come up in the future thanks to the advanced supply chain technologies and processes that were used to build them. Digital tools that help companies understand and evaluate Big Data make their supply lines much more reliable. Computer programs that use AI can combine various sets of data from inside and outside the business. You can look at news stories, sales records, competitor behavior, and even notes from customers all at the same time to spot patterns and opportunities.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the projected growth of the Osteoarthritis market?

The Osteoarthritis market is the expected increase in total market value of 13.37 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Osteoarthritis market?

Osteoarthritis market size was valued at approximately 5.12 billion USD in 2024. This figure will reach 13.37 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Osteoarthritis market?

Osteoarthritis market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

How much will the Osteoarthritis market be worth by 2035?

Osteoarthritis market is expected to be worth of 13.37 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Osteoarthritis market perform over the next 10 years?

Over the next 10 years the Osteoarthritis market is expected to shift from usd billion 5.12 to 13.37 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the Osteoarthritis market?

North America had the largest share in the market

Who are the key players in the Osteoarthritis market?

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.

Market Summary

As per MRFR analysis, the Osteoarthritis Market Size was estimated at 5.12 USD Billion in 2024. The Osteoarthritis industry is projected to grow from 5.58 in 2025 to 13.37 by 2035, exhibiting a compound annual growth rate (CAGR) of 9.12 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Osteoarthritis Market is experiencing transformative growth driven by innovative treatment approaches and demographic shifts.

  • The rise of biologics and targeted therapies is reshaping treatment paradigms in the Osteoarthritis Market.
  • Personalized treatment approaches are gaining traction, particularly in North America, where patient-centric care is prioritized.
  • Integration of digital health solutions is enhancing patient engagement and monitoring, especially in the Asia-Pacific region.
  • The aging population and rising obesity rates are significant drivers propelling market expansion, particularly in pain management and hospital segments.

Market Size & Forecast

2024 Market Size 5.12 (USD Billion)
2035 Market Size 13.37 (USD Billion)
CAGR (2025 - 2035) 9.12%
Largest Regional Market Share in 2024 North America

Major Players

<p>Pfizer (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)</p>

Market Trends

The Osteoarthritis Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding joint health and the rising prevalence of osteoarthritis among aging populations are contributing to a heightened demand for effective treatment options. Furthermore, advancements in medical technology and the development of innovative therapies are reshaping the landscape of this market. Pharmaceutical companies are focusing on research and development to introduce novel drugs and biologics that target the underlying causes of osteoarthritis, rather than merely alleviating symptoms. This shift towards more comprehensive treatment approaches appears to be a pivotal trend in the Osteoarthritis Market. In addition, the growing emphasis on personalized medicine is influencing treatment strategies, as healthcare providers seek to tailor interventions to individual patient needs. The integration of digital health solutions, such as telemedicine and mobile health applications, is also gaining traction, enabling patients to manage their conditions more effectively. As the Osteoarthritis Market evolves, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly to meet the changing demands of patients and healthcare systems.

Rise of Biologics and Targeted Therapies

The Osteoarthritis Market is witnessing a shift towards biologics and targeted therapies that aim to address the root causes of the condition. These innovative treatments focus on modulating the immune response and promoting cartilage repair, potentially offering more effective solutions compared to traditional pain management approaches.

Personalized Treatment Approaches

There is a growing trend towards personalized treatment strategies in the Osteoarthritis Market. Healthcare providers are increasingly recognizing the importance of tailoring interventions based on individual patient profiles, which may enhance treatment efficacy and improve patient outcomes.

Integration of Digital Health Solutions

The incorporation of digital health technologies is transforming the Osteoarthritis Market. Telemedicine and mobile applications are becoming essential tools for patient management, allowing for better monitoring of symptoms and facilitating communication between patients and healthcare professionals.

Osteoarthritis Market Market Drivers

Market Growth Projections

The Global Osteoarthritis Market Industry is poised for substantial growth, with projections indicating a market size of 5.12 USD Billion in 2024 and an anticipated increase to 13.4 USD Billion by 2035. This growth trajectory suggests a robust demand for osteoarthritis treatments and management solutions. The compound annual growth rate (CAGR) of 9.12% from 2025 to 2035 reflects the increasing recognition of osteoarthritis as a significant public health issue. As stakeholders in the healthcare sector respond to this demand, the market is likely to witness innovations and enhancements in treatment options, further solidifying its growth potential.

Growing Awareness and Education

The rising awareness and education surrounding osteoarthritis are crucial drivers of the Global Osteoarthritis Market Industry. Public health campaigns and educational initiatives are increasingly informing individuals about the disease, its risk factors, and management strategies. This heightened awareness encourages early diagnosis and treatment, which can lead to better health outcomes. Moreover, healthcare professionals are receiving enhanced training on osteoarthritis management, further promoting effective treatment options. As patients become more informed about their condition, they are more likely to seek medical advice and treatment, thereby driving market growth and fostering a proactive approach to managing osteoarthritis.

Increased Healthcare Expenditure

Growing healthcare expenditure across various regions is likely to bolster the Global Osteoarthritis Market Industry. As countries invest more in healthcare infrastructure and services, the availability and accessibility of osteoarthritis treatments improve. For instance, nations with higher healthcare budgets are more capable of funding advanced therapies and technologies. This trend is particularly evident in developed economies, where healthcare spending is projected to rise significantly in the coming years. The increased allocation of resources towards chronic disease management, including osteoarthritis, suggests a favorable environment for market expansion, potentially leading to a compound annual growth rate (CAGR) of 9.12% from 2025 to 2035.

Advancements in Treatment Options

Innovations in treatment modalities for osteoarthritis are propelling the Global Osteoarthritis Market Industry forward. Recent developments in pharmaceuticals, biologics, and regenerative medicine offer new avenues for managing symptoms and improving patient outcomes. For instance, the introduction of disease-modifying osteoarthritis drugs (DMOADs) aims to slow disease progression, which could alter the treatment landscape. Furthermore, minimally invasive surgical techniques are gaining traction, providing patients with effective alternatives to traditional surgery. These advancements not only enhance the quality of life for patients but also contribute to market growth, as healthcare providers seek to adopt the latest evidence-based practices.

Rising Prevalence of Osteoarthritis

The increasing prevalence of osteoarthritis globally is a primary driver of the Global Osteoarthritis Market Industry. As populations age, the incidence of osteoarthritis is expected to rise significantly. In 2024, the market is projected to reach 5.12 USD Billion, reflecting the growing need for effective treatments and management strategies. The World Health Organization indicates that osteoarthritis affects approximately 10% of the global population over 60 years, highlighting the urgency for innovative solutions. This trend is likely to continue, with projections suggesting that by 2035, the market could expand to 13.4 USD Billion, driven by the aging demographic and the associated healthcare demands.

Emerging Markets and Demographic Shifts

Emerging markets are becoming increasingly significant in the Global Osteoarthritis Market Industry due to demographic shifts and economic development. Countries in Asia-Pacific and Latin America are witnessing rapid urbanization and an increase in life expectancy, leading to a higher prevalence of osteoarthritis. As these regions develop economically, there is a growing demand for healthcare services and treatments. This trend is expected to create new opportunities for market players, as they seek to cater to the unique needs of these populations. The expansion into emerging markets could play a pivotal role in achieving the projected market growth, with a CAGR of 9.12% anticipated from 2025 to 2035.

Market Segment Insights

By Application: Pain Management (Largest) vs. Joint Function Improvement (Fastest-Growing)

<p>In the Osteoarthritis Market, the application segments demonstrate varying levels of significance, with Pain Management taking the lead. This segment is primarily focused on pharmacological approaches, which remain highly preferred among patients seeking relief from chronic pain associated with osteoarthritis. Meanwhile, Joint Function Improvement is emerging as a significant trend, catering to an increasing demand for enhancing mobility and effectiveness in daily activities. This dichotomy illustrates a system where immediate relief and long-term functionality are both essential to patients. As the population ages, the need for effective interventions in osteoarthritis is driving growth across all segments. Pain Management continues to dominate, yet emerging solutions aimed at improving joint function show promise for accelerated growth. Key drivers include advancements in non-invasive therapies and an increasing focus on personalized medicine, ensuring that new treatments cater to individual patient needs and improvement objectives.</p>

<p>Pain Management (Dominant) vs. Surgical Intervention (Emerging)</p>

<p>In the context of the Osteoarthritis Market, Pain Management stands out as the dominant application segment, focusing on pharmacological solutions designed to address chronic pain. This segment includes over-the-counter medications and prescription drugs that provide timely relief, appealing greatly to patients prioritizing comfort. In contrast, Surgical Intervention, while regarded as an emerging application, is gaining traction as a necessary option for patients whose conditions do not improve with conventional treatments. Surgical methods, including arthroscopy and joint replacement, offer lasting solutions that resonate with those seeking a definitive way to restore mobility and alleviate pain. The contrasting nature of these two segments reflects the multifaceted approach required to manage osteoarthritis effectively.</p>

By End Use: Hospitals (Largest) vs. Home Care (Fastest-Growing)

<p>In the Osteoarthritis Market, hospitals hold the largest share among various end-use segments. This is primarily due to their comprehensive infrastructure and availability of advanced treatment options. Clinics also contribute significantly to the market, offering specialized care that addresses the needs of osteoarthritis patients. Home care is emerging rapidly, becoming increasingly preferred by patients who seek convenience and personalized care. Rehabilitation centers play a crucial role as well, providing targeted therapies that aid recovery and improve quality of life.</p>

<p>Hospitals (Dominant) vs. Home Care (Emerging)</p>

<p>Hospitals have established themselves as the dominant force in the Osteoarthritis Market due to their multidisciplinary approach and access to a wide array of specialists. They offer advanced surgical options, pain management, and rehabilitation services, catering to a diverse patient population. On the other hand, home care is rapidly emerging as a preferred choice for many patients who prioritize comfort and flexibility in managing their condition. The growing trend towards telehealth services and remote monitoring has further facilitated this shift, making home care more accessible and appealing. While hospitals remain vital for acute care, home care solutions are increasingly recognized for their role in ongoing management and support.</p>

By Product Type: Pharmaceuticals (Largest) vs. Medical Devices (Fastest-Growing)

<p>The Osteoarthritis Market is significantly shaped by various product types, with Pharmaceuticals holding the largest market share. This segment includes traditional and novel drug therapies targeting pain relief and inflammation associated with osteoarthritis. Following Pharmaceuticals, Medical Devices have emerged as a key segment, playing a critical role in managing osteoarthritis symptoms through physical interventions. The segment distribution highlights a balanced interest in both medication and assistive technology, which is vital for comprehensive management of the condition.</p>

<p>Pharmaceuticals (Dominant) vs. Therapeutic Equipment (Emerging)</p>

<p>In the Osteoarthritis Market, Pharmaceuticals dominate as they represent the cornerstone for therapeutic intervention, utilizing a range of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Their proven efficacy and widespread acceptance among healthcare professionals make them a go-to choice for many patients. Conversely, Therapeutic Equipment, which includes items like braces and physical therapy devices, is emerging as a significant player. While currently less dominant, this segment's growth is driven by increasing consumer awareness about non-pharmacological treatment options, which emphasize improving mobility and reducing pain without side effects typically associated with medications.</p>

By Treatment Type: Medication (Largest) vs. Physical Therapy (Fastest-Growing)

<p>In the Osteoarthritis Market, the market share distribution among treatment types shows a significant preference for medication, which remains the largest segment. This is driven by the widespread availability of non-steroidal anti-inflammatory drugs (NSAIDs) and other pain-relieving medications that are commonly prescribed. Surgical options are also notable, but they account for a smaller proportion compared to medication-based treatments. Physical therapy, while currently lower in share, is gaining traction as patients increasingly seek non-invasive alternatives for pain management.</p>

<p>Medication (Dominant) vs. Physical Therapy (Emerging)</p>

<p>Medication is the dominant treatment option in the Osteoarthritis Market, primarily due to its accessibility and effectiveness in managing symptoms. Patients can conveniently obtain various medication forms, including oral, topical, and injectable treatments, often without the need for extensive medical supervision. In contrast, physical therapy is emerging as a vital non-invasive treatment, emphasizing rehabilitation and strengthening exercises. Its growing popularity is attributed to an increasing recognition of holistic approaches to manage osteoarthritis, in line with patient preferences for avoiding surgery. As awareness and acceptance of physical therapy expand, it positions itself as a promising alternative in the treatment landscape.</p>

Get more detailed insights about Osteoarthritis Market Research Report – Forecast Till 2035

Regional Insights

North America : Market Leader in Osteoarthritis

North America is poised to maintain its leadership in the osteoarthritis market, holding a significant share of 2.56B in 2024. The region's growth is driven by an aging population, increasing obesity rates, and heightened awareness of osteoarthritis treatments. Regulatory support and advancements in medical technology further catalyze market expansion, with a focus on innovative therapies and patient-centric solutions. The competitive landscape is robust, featuring key players such as Pfizer, Johnson & Johnson, and AbbVie. The U.S. remains the largest market, supported by extensive healthcare infrastructure and research initiatives. Companies are investing in R&D to develop novel treatments, ensuring a dynamic market environment that addresses the evolving needs of patients and healthcare providers.

Europe : Emerging Market with Growth Potential

Europe's osteoarthritis market is valued at 1.52B, reflecting a growing demand for effective treatments. Factors such as an aging demographic, rising healthcare expenditure, and increasing prevalence of obesity contribute to market growth. Regulatory frameworks in the EU are evolving to support innovative therapies, enhancing patient access to advanced treatments. Leading countries like Germany, France, and the UK are at the forefront of this market, with a competitive landscape featuring major players like Novartis and Roche. The presence of strong healthcare systems and ongoing clinical trials further bolster the market. As companies focus on personalized medicine and biologics, Europe is set to become a key player in The Osteoarthritis.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region, with a market size of 0.88B, is experiencing rapid growth in the osteoarthritis sector. Factors such as increasing urbanization, lifestyle changes, and a rising elderly population are driving demand for osteoarthritis treatments. Governments are also implementing health initiatives to address the rising burden of chronic diseases, including osteoarthritis. Countries like Japan, China, and Australia are leading the market, with a mix of local and international players. Companies such as Amgen and Sanofi are expanding their presence, focusing on innovative therapies and partnerships. The competitive landscape is evolving, with an emphasis on research and development to meet the unique needs of the region's diverse population.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region, with a market size of 0.16B, presents unique challenges and opportunities in the osteoarthritis market. Factors such as limited healthcare access, varying economic conditions, and a growing prevalence of lifestyle-related diseases impact market growth. However, increasing awareness and government initiatives to improve healthcare infrastructure are positive signs for the future. Countries like South Africa and the UAE are leading the market, with a focus on improving treatment access and quality. The competitive landscape includes both local and international players, but the market remains underdeveloped compared to other regions. As healthcare systems evolve, there is potential for growth in innovative treatment options and patient care.

Key Players and Competitive Insights

The Osteoarthritis Market is currently characterized by a dynamic competitive landscape, driven by an increasing prevalence of the condition and a growing demand for effective treatment options. Key players such as Pfizer (US), Johnson & Johnson (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and biologics. These companies are actively pursuing partnerships and collaborations to enhance their product portfolios, thereby shaping a competitive environment that emphasizes both innovation and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. The collective influence of these key players is significant, as they not only drive technological advancements but also set industry standards that smaller companies often follow.

In November 2025, Pfizer (US) announced a strategic partnership with a leading biotech firm to co-develop a novel gene therapy aimed at osteoarthritis treatment. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, indicating Pfizer's commitment to innovation in the osteoarthritis space. Such partnerships may also provide Pfizer with a competitive edge in a market that increasingly values cutting-edge solutions.

In October 2025, Johnson & Johnson (US) launched a new digital health platform designed to support osteoarthritis patients in managing their condition through personalized treatment plans. This initiative reflects the company's focus on integrating technology into healthcare, potentially improving patient outcomes and engagement. By leveraging digital tools, Johnson & Johnson aims to differentiate itself in a crowded market, aligning with current trends towards digitalization in healthcare.

In September 2025, AbbVie (US) expanded its clinical trial program for a promising new biologic therapy targeting osteoarthritis. This expansion not only underscores AbbVie's commitment to advancing treatment options but also positions the company to capture a larger market share as the therapy progresses through regulatory pathways. The strategic emphasis on clinical research and development is likely to enhance AbbVie's reputation as a leader in innovative osteoarthritis treatments.

As of December 2025, current competitive trends in the Osteoarthritis Market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can reliably navigate supply chain complexities while delivering cutting-edge solutions are likely to emerge as leaders in this evolving market.

Key Companies in the Osteoarthritis Market include

Industry Developments

Robexera, the first generic robenacoxib medication, will be available in 2023, according to Krka. It is intended to treat pain and inflammation brought on by soft tissue surgery and persistent osteoarthritis (OA) in dogs. A once-daily dosage schedule for Robexera, a COX2 NSAID formulation, provides anti-inflammatory pain relief2,3,4.  The medicine comes in the form of a chewable tablet with flavoring to make it easier for pet owners to administer. It comes in four strengths for ease of administering, and each pack includes a set of PIL sheets that can be converted into prescription envelopes, color-coded boxes, and perforated blisters.

The U.S. Food and Drug Administration (U.S. FDA) has granted Zydus Lifesciences final permission in 2023 to produce and distribute 50 mg/200 mcg and 75 mg/200 mcg of Misoprostol Delayed Release Tablets USP, as well as 0.5 mg and 1 mg of Varenicline tablets. Arthrotec Delayed-Release tablets are the reference listed drug (RLD) for Diclofenac Sodium and Misoprostol Delayed Release Tablets. These tablets are intended to treat rheumatoid arthritis and osteoarthritis in individuals who are at high risk of developing stomach or intestinal ulcers. According to Zydus, the medication would be produced at the group's Ahmedabad formulation manufacturing facility.

The product's annual sales in the United States were $13 million, according to the business, which cited IQVIA MAT March 2023 numbers.

September 2022: StemOne, the off-the-shelf cell therapy product by Alkem Laboratories, received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. This product is being launched in collaboration with Stempeutics, which aims to treat knee osteoarthritis, a degenerative joint disease.

August 2022: Shionogi & Co., Ltd. and Grünenthal GmbH have entered into a licensing agreement to jointly market and commercialize injectable resiniferatoxin in Japan. Resiniferatoxin is a pipeline product developed by Grünenthal, and it is intended to treat pain caused by osteoarthritis of the knee. The licensing agreement will allow the companies to bring the product to market in Japan, offering a new treatment option for patients with knee osteoarthritis.

Future Outlook

Osteoarthritis Market Future Outlook

<p>The Osteoarthritis Market is projected to grow at a 9.12% CAGR from 2024 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.</p>

New opportunities lie in:

  • <p>Development of personalized treatment plans leveraging AI analytics.</p>
  • <p>Expansion of telehealth services for remote patient monitoring.</p>
  • <p>Investment in regenerative medicine technologies for joint repair.</p>

<p>By 2035, the Osteoarthritis Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.</p>

Market Segmentation

Osteoarthritis Market End Use Outlook

  • Hospitals
  • Clinics
  • Home Care
  • Rehabilitation Centers

Osteoarthritis Market Application Outlook

  • Pain Management
  • Joint Function Improvement
  • Physical Therapy
  • Surgical Intervention

Osteoarthritis Market Product Type Outlook

  • Pharmaceuticals
  • Medical Devices
  • Therapeutic Equipment
  • Nutraceuticals

Osteoarthritis Market Treatment Type Outlook

  • Non-Surgical
  • Surgical
  • Physical Therapy
  • Medication

Report Scope

MARKET SIZE 20245.12(USD Billion)
MARKET SIZE 20255.58(USD Billion)
MARKET SIZE 203513.37(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)9.12% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledPfizer (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)
Segments CoveredApplication, End Use, Product Type, Treatment Type
Key Market OpportunitiesAdvancements in personalized medicine and digital therapeutics enhance treatment options in the Osteoarthritis Market.
Key Market DynamicsRising demand for innovative therapies drives competitive forces and technological advancements in the Osteoarthritis Market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected growth of the Osteoarthritis market?

The Osteoarthritis market is the expected increase in total market value of 13.37 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Osteoarthritis market?

Osteoarthritis market size was valued at approximately 5.12 billion USD in 2024. This figure will reach 13.37 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Osteoarthritis market?

Osteoarthritis market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

How much will the Osteoarthritis market be worth by 2035?

Osteoarthritis market is expected to be worth of 13.37 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Osteoarthritis market perform over the next 10 years?

Over the next 10 years the Osteoarthritis market is expected to shift from usd billion 5.12 to 13.37 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the Osteoarthritis market?

North America had the largest share in the market

Who are the key players in the Osteoarthritis market?

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp &amp; Dohme Corp.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | 2.2 RESEARCH METHODOLOGY
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | 3.2 MARKET FACTOR ANALYSIS
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Billion)
    2. | 4.2 Healthcare, BY End Use (USD Billion)
    3. | 4.3 Healthcare, BY Product Type (USD Billion)
    4. | 4.4 Healthcare, BY Treatment Type (USD Billion)
    5. | 4.5 Healthcare, BY Region (USD Billion)
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | 5.2 Company Profiles
    3. | 5.3 Appendix

Osteoarthritis Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions